3687-18-1

Tramiprosate is a sulfated glycosaminoglycan mimetic that was reported to bind soluble Aβ and inhibit the interaction of Aβ with endogenous glycosaminoglycans, thereby preventing β-sheet formation. Conversely, tramiprosate was also reported to promote tau polymerization into fibrillar aggregates. It is also an analog of GABA that can act as a partial agonist of GABA_A receptors, as well as an antagonist at GABA_B receptors.

White Powder

Important gaba mimetic agent. It evokes neurological responses similar to those elicited by g-aminobutyric acid

ChEBI: 3-Aminopropanesulfonate is an organosulfonic acid.

Sulfated glycosaminoglycan (sGAG) mimetic that targets soluble amyloid β (A β ) and maintains A β in a non-fibrillar form. Decreases A β 42-induced neuronal death and inhibits amyloid deposition in vitro . Decreases brain amyloid plaque load by 30%, increases tau polymerization and is brain penetrant. Also a GABA analog that protects against the convulsant and cytotoxic activity of kainic acid in vivo .

Store at -20°C

[1] De Souza, F.I., Zumiotti, A.V., and Da Silva, C.F. Neuregulins 1-α and 1-β on the regeneration the peripheral nerves[J]. Acta Ortop Bras.
[2] ISMAEL SANTA-MARIA. Tramiprosate, a drug of potential interest for the treatment of Alzheimer’s disease, promotes an abnormal aggregation of tau.[J]. Molecular Neurodegeneration, 2007: 17. DOI: 10.1186/1750-1326-2-17
[3] A. GIOTTI. Homotaurine: a GABAB antagonist in guinea-pig ileum[J]. British Journal of Pharmacology, 1983, 79 4: 855-862. DOI: 10.1111/j.1476-5381.1983.tb10529.x